GeneOne Life Science, Inc. obtained European Patent EP4061416A1 for compositions containing Powassan viral antigens useful for vaccination and treatment of patients. The patent application was filed by inventors MASLOW, Joel, JEONG, Moonsup, ROBERTS, Christine, CHO, Youngran, and PARK, Young, covering the vaccine composition (A61K 39/12), therapeutic uses (A61P 31/14), protein sequences (C07K 14/005), and viral preparations (C12N 7/00). The patent is designated for all EU contracting states and additional European countries.

Pharmaceutical and biotech companies developing flavivirus vaccines should review this patent to understand existing IP landscape for Powassan virus immunizations. IP counsel should assess Freedom to Operate for any competing vaccine programs targeting Powassan or related tick-borne viruses. No immediate compliance deadlines apply as this is a patent grant rather than a regulatory requirement.